New Biotechnology Company: Immunovo BV
Immunovo BV secures seed funding from Dutch venture capital firms
The technology involves the application of novel and proprietary techniques in synthetic immunogen development. Immunovo is a spin-out from Pepscan Therapeutics in Lelystad. Its technology platform is based on the work of Pepscan’s founding scientist Professor Rob Meloen. The new company is managed by Dr. Joost van Bree (Chief Executive Officer) and Dr. Evert Jan Schenkelaars (Chief Medical Officer) and is based in ‘s-Hertogenbosch.
“We are truly excited to have created this exciting new company based upon such an innovative technology. Immunovo aims to develop its proprietary technology to create a pipeline of immunotherapeutic drugs which have the potential to be truly potent and effective medicines’’ said Joost van Bree.
As part of the seed funding, founding investors Jan van der Hoeven, Biox Biosciences and Cees de Wolff, Lupus Ventures, will join the Board of Directors.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.